PIK3CA and breast carcinoma: Pictilisib also known as GDC-0941 is a highly selective orally active class I PI3K inhibitor that has shown promising efficacy with tolerable side effects in preclinical advanced breast cancer and solid tumors, however in human trials clinical regression of tumors was not seen.